Evidence map›Paper›PMID 27177952›Full record

ArticleSurgical endoscopy2017

Type 2 diabetes remission following gastric bypass: does diarem stand the test of time?

J Hunter Mehaffey, Mathew G Mullen, Rachel L Mehaffey, Florence E Turrentine, Steven K Malin, Jennifer L Kirby, Bruce Schirmer, Peter T Hallowell

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Surgical endoscopy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Trial
  2. Article
  3. Metabolic disease remission after Roux-en-Y gastric bypass depends on preoperative disease severity: use of a new objective metabolic scoring system.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · 2024
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. DiaRem2: Incorporating duration of diabetes to improve prediction of diabetes remission after metabolic surgery.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · 2019
    Article
  10. Article
  11. Article
  12. Review
  13. Roux-en-Y gastric bypass is safe in elderly patients: a propensity-score matched analysis.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · 2018
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

J Hunter MehaffeyDepartment of Surgery, University of Virginia, Box 800709, Charlottesville, VA, 22903, USA. jhm9t@virginia.edu.
Mathew G MullenDepartment of Surgery, University of Virginia, Box 800709, Charlottesville, VA, 22903, USA.
Rachel L MehaffeyDepartment of Internal Medicine, University of Virginia, Box 800709, Charlottesville, VA, 22903, USA.
Florence E TurrentineDepartment of Surgery, University of Virginia, Box 800709, Charlottesville, VA, 22903, USA.
Steven K MalinDepartment of Kinesiology, University of Virginia, Box 800709, Charlottesville, VA, 22903, USA.
Jennifer L KirbyDepartment of Internal Medicine, University of Virginia, Box 800709, Charlottesville, VA, 22903, USA.
Bruce SchirmerDepartment of Surgery, University of Virginia, Box 800709, Charlottesville, VA, 22903, USA.
Peter T HallowellDepartment of Surgery, University of Virginia, Box 800709, Charlottesville, VA, 22903, USA.

Funding

Cardiovascular Surgery Training ProgramT32HL007849 · NHLBI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI KRON, IRVING L., LAUBACH, VICTOR E · 1998 to 2025
$7.0M
NHLBI NIH HHS T32 HL007849
6 · The paper itself

Abstract

OBJECTIVE(S): Roux-en-Y Gastric Bypass (RYGB) is well known to ameliorate type 2 diabetes mellitus (T2DM), and recent work suggests that the preoperative DiaREM model predicts successful remission up to 1 year post-RYGB. However, no data exist for long-term validity. Therefore, we sought to determine the utility of this score on long-term RYGB effectiveness for T2DM resolution at 2 and 10 years, respectively.

methodsT2DM patients (Age: 48, BMI: 49, HbA

resultsAmong RYGB patients with 2-year postoperative data, 2 were lost (n = 1 no follow-up and n = 1 died) resulting in 57 patients for analysis. For the 10-year postoperative data, 11 were lost (n = 6 no follow-up and n = 5 died), thereby resulting in only 31 patients for analysis. Patients were distributed by DiaREM score to correlate with the predicted probability of remission as follows: 0-2 (Predicted 94 %, 2-year 100 % p = 0.61, 10-year 100 % p = 0.72), 3-7 (Predicted 76 %, 2-year 94 % p = 0.08, 10-year 83 % p = 0.57), 8-12 (Predicted 36 %, 2-year 47 % p = 0.38, 10-year 43 % p = 0.72), 13-17 (Predicted 22 %, 2-year 20 % p = 0.92, 10-year 33 % p = 0.64), and 18-22 (Predicted 9 %, 2-year 15 % p = 0.40, 10-year 14 % p = 0.64).

conclusionsPreoperative DiaREM scores are a good tool for predicting both short- and long-term T2DM remissions following RYGB. This study highlights the need to identify strategies that improve T2DM remission in those at highest risk.

Indexed as

Decision Support TechniquesGastric BypassHealth Status IndicatorsAdultAgedAged, 80 and overDatabases, FactualDiabetes Mellitus, Type 2FemaleFollow-Up StudiesHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeBariatric surgeryDiabetes remissionDiaREMObesity

Identifiers

PMID27177952
PMCPMC5107360

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.